Novartis Sues Alvogen To Block Generic Dementia Patch

Law360, New York (January 7, 2013, 7:54 PM EST) -- Novartis AG slapped generic-drug maker Alvogen Group Inc. with a lawsuit in Delaware on Friday, accusing Alvogen of infringing two patents by seeking U.S. regulatory approval to make and sell generic versions of the Exelon patch, a dementia treatment.

Patent co-owners Novartis and LTS Lohmann Therapie-Systeme AG targeted Alvogen and a Pine Brook, N.J.-based Alvogen subsidiary, asking the court to rule that Alvogen had infringed the patent-in-suit and order that the approval of Alvogen's bid for approval of its proposed rivastigmine transdermal products can't come before...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.